Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs M 6620 (Primary)
- Indications Brain metastases; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions
- 13 Dec 2017 Status changed from suspended to recruiting.
- 16 Nov 2017 Status changed from recruiting to suspended.
- 10 Jun 2017 Biomarkers information updated